Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Sage Therapeutics Inc (NASDAQ: SAGE) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Sage Therapeutics Inc (NASDAQ: SAGE) concerning whether a series of statements by Sage Therapeutics Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On March 23, 2016, Kerrisdale Capital published a report on Sage Therapeutics, claiming that Sage Therapeutics main drug SAGE-547, “is little more than a Band-Aid, achieving, at best, a temporary reduction in brain activity – very similar to many other treatments that doctors already use." The Report also claimed Sage Therapeutics potentially overestimated the size of the drug's target market by a factor of 6. 

Following this news, NASDAQ: SAGE shares declined approximately 20% during heavy intra-day trading on March 23, 2016.

Based in Cambridge, Massachusetts, and founded in 2010 Sage Therapeutics Inc is engaged in developing and commercializing novel medicines to treat central nervous system disorders.

If you purchased shares of Sage Therapeutics Inc (NASDAQ: SAGE) on or before March 23, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185